Sign In
Buy BGNE
$184.71
+0 (+0%)
At Close: Mar 28, 2025
EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China
07:00am, Monday, 25'th Jan 2021
HEMEL HEMPSTEAD, England & BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Applica
Week In Review: BeiGene Signs $2.2 Billion Deal With Novartis For PD-1
05:15pm, Sunday, 17'th Jan 2021
BeiGene out-licensed ex-China rights for tislelizumab, its China-approved anti-PD-1 antibody, to Novartis in a $2.2 billion agreement. Inmagene in-licensed global rights to four novel pre-clinical imm
BeiGene (BGNE) Up on Label Expansion of Tislelizumab in China
10:32am, Friday, 15'th Jan 2021
BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene's anti-PD-1 antibody received approval in China in first-line advanced squamous non-small cell lung cancer.
Novartis (NVS) In-Licenses Anti-PD-1 Antibody from BeiGene
03:48pm, Tuesday, 12'th Jan 2021
Novartis (NVS) in-licenses BeiGene's anti-PD-1 monoclonal antibody, tislelizumab, in major markets outside of China.
BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab
04:30pm, Monday, 11'th Jan 2021
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene and Novartis enter into a collaboration to develop, manufacture and commercialize tislelizumab, BeiGene's anti-PD-1 antibody.
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--Strand Therapeutics and BeiGene entered an option and license agreement aimed at developing, commercializing Strand's mRNA treatments for s
Week In Review: DXY Raises $500 Million For Online Consumer Healthcare Site
03:08pm, Sunday, 03'rd Jan 2021
Week In Review: DXY Raises $500 Million For Online Consumer Healthcare Site
BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL)
11:00pm, Sunday, 27'th Dec 2020
BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces inclusion of three innovative oncology products in China National Reimbursement Drug List (NRDL).
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces that BLINCYTO® (blinatumomab) for injection has been approved in China in relapsed/refractory B-cell precursor ALL.
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH20--BeiGene announces clinical data on BTK inhibitor BRUKINSA (zanubrutinib) in B-cell malignancies and Waldenström's at the 62nd ASH annual
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH20--BeiGene presents data on BTK inhibitor BRUKINSA in marginal zone lymphoma and chronic lymphocytic leukemia at the 62nd ASH Annual Meeting.
BeiGene Announces Pricing of Public Offering by Selling Shareholders
11:00pm, Tuesday, 01'st Dec 2020
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative me
BeiGene Launches Proposed Public Offering by Selling Shareholders
04:15pm, Tuesday, 01'st Dec 2020
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative me
BeiGene to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
07:00am, Monday, 23'rd Nov 2020
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative
